Research ArticleCancer

Matrix-binding checkpoint immunotherapies enhance antitumor efficacy and reduce adverse events

See allHide authors and affiliations

Science Translational Medicine  08 Nov 2017:
Vol. 9, Issue 415, eaan0401
DOI: 10.1126/scitranslmed.aan0401

Article Information

vol. 9 no. 415

PubMed: 
Print ISSN: 
Online ISSN: 
History: 
  • Received for publication June 5, 2017
  • Accepted for publication September 27, 2017

Author Information

  1. Jun Ishihara1,2,
  2. Kazuto Fukunaga1,2,3,*,
  3. Ako Ishihara1,*,
  4. Hans M. Larsson2,
  5. Lambert Potin1,2,
  6. Peyman Hosseinchi1,
  7. Gabriele Galliverti2,
  8. Melody A. Swartz1,2,4,5 and
  9. Jeffrey A. Hubbell1,2,5,
  1. 1Institute for Molecular Engineering, University of Chicago, Chicago, IL 60637, USA.
  2. 2Institute of Bioengineering, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
  3. 3Department of Bioengineering, Tokyo Institute of Technology, 226-8501 Yokohama, Kanagawa, Japan.
  4. 4Swiss Institute for Experimental Cancer Research, School of Life Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
  5. 5Institute of Chemical Sciences and Engineering, School of Basic Sciences, Ecole Polytechnique Fédérale de Lausanne, CH-1015 Lausanne, Switzerland.
  1. Corresponding author. Email: jhubbell{at}uchicago.edu
    • * These authors contributed equally to this work.

    Altmetric

    Article usage

    Article usage: November 2017 to November 2017

    AbstractFullPdf
    Nov 201785354571091